Skip to main content Skip to section navigation Skip to footer
Lexaria Bioscience Corp.Lexaria BioscienceLexaria Bioscience
Lexaria Bioscience Corp.

NASDAQ:LEXX; NASDAQ WARRANT:LEXXW

  • Home
  • About
    • Management
    • Board of Directors
    • Advisors & Consultants
  • Technology
    • Overview
    • Commercial Applications
    • Research
    • Patent Portfolio
  • Licensing Opportunities
  • Investors
Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Presentations
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • 2022 Annual General Meeting
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Legend Removal
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
May 10, 2017 8:00am EDT

Lexaria Announces Research on Nonsteroidal Anti-Inflammatory Drugs

May 04, 2017 8:00am EDT

Lexaria Announces R&D on Nicotine

May 02, 2017 8:05am EDT

Lexaria Announces Million Dollar Research and Development Program

Apr 18, 2017 8:05am EDT

Lexaria Welcomes Canada's Proposed Cannabis Legislation

Apr 10, 2017 8:00am EDT

Lexaria and Neutrisci Enter Cannabinoid Joint Venture

Mar 22, 2017 8:05am EDT

Lexaria Introduces TurboCBD(TM) Brand of High Absorption Full Spectrum Hemp Oil Capsules

Mar 14, 2017 8:05am EDT

Design Phase Underway for Studies to be Conducted by National Research Council and Lexaria

Feb 27, 2017 8:00am EST

Lexaria Receives Notice of its First Patent to be Granted in Australia for Cannabinoid Infused Edibles

Feb 08, 2017 8:00am EST

Lexaria Signs Master Collaborative Research Agreement

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Lexaria Bioscience Corp. (NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

250.765.6424
info@lexariabioscience.com

Lexaria Bioscience Corp.
#100-740 McCurdy Road
Kelowna, BC, V1X2P7

Privacy Policy

General Disclaimer:
No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases…

Read More

Copyright ©2023 All rights reserved.

Back to the top